Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)
- PMID: 19394035
- PMCID: PMC5884059
- DOI: 10.1016/j.jpeds.2009.02.007
Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)
Abstract
Objective: To identify key factors for the delay in diagnosis of Duchenne muscular dystrophy (DMD) without known family history.
Study design: The cohort comes from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), a multistate, multiple-source, population-based surveillance system that identifies and gathers information on all cases of Duchenne and Becker muscular dystrophy born since 1982. We analyzed medical records of 453 Duchenne and Becker muscular dystrophy boys to document the time course and steps taken to reach a definitive diagnosis.
Results: Among 156 boys without known family history of DMD prior to birth, first signs or symptoms were noted at a mean age of 2.5 years. Concerns resulted in primary care provider evaluation of the child at a mean age of 3.6 years. Mean age at time of initial creatine kinase was 4.7 years. Mean age at definitive diagnosis of DMD was 4.9 years.
Conclusions: There is a delay of about 2.5 years between onset of DMD symptoms and the time of definitive diagnosis, unchanged over the previous 2 decades. This delay results in lost opportunities for timely genetic counseling and initiation of corticosteroid treatment. We recommend checking creatine kinase early in the evaluation of boys with unexplained developmental delay.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Comment in
-
Missed opportunities for duchenne muscular dystrophy.J Pediatr. 2009 Sep;155(3):309-10. doi: 10.1016/j.jpeds.2009.03.034. J Pediatr. 2009. PMID: 19732575 No abstract available.
-
Muscular dystrophy revealed by incidentally discovered elevated aminotransferase levels.J Pediatr. 2010 Apr;156(4):689. doi: 10.1016/j.jpeds.2009.11.047. Epub 2010 Feb 6. J Pediatr. 2010. PMID: 20138302 No abstract available.
Similar articles
-
Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000-2015.Muscle Nerve. 2022 Aug;66(2):193-197. doi: 10.1002/mus.27532. Epub 2022 Apr 11. Muscle Nerve. 2022. PMID: 35312090 Free PMC article.
-
Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy.J Child Neurol. 2010 Sep;25(9):1098-102. doi: 10.1177/0883073810371001. J Child Neurol. 2010. PMID: 20817884 Free PMC article.
-
Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet.J Pediatr Rehabil Med. 2016;9(1):5-11. doi: 10.3233/PRM-160361. J Pediatr Rehabil Med. 2016. PMID: 26966795 Free PMC article.
-
Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.JAMA Neurol. 2016 Jan;73(1):111-6. doi: 10.1001/jamaneurol.2015.3537. JAMA Neurol. 2016. PMID: 26594870 Review.
-
Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.Pediatr Clin North Am. 2015 Jun;62(3):723-42. doi: 10.1016/j.pcl.2015.03.008. Epub 2015 Apr 20. Pediatr Clin North Am. 2015. PMID: 26022172 Review.
Cited by
-
Age-Related Blood Levels of Creatine Kinase-MM in Newborns and Patients with Duchenne Muscular Dystrophy: Considerations for the Development of Newborn Screening Algorithms.Int J Neonatal Screen. 2024 Jun 19;10(2):41. doi: 10.3390/ijns10020041. Int J Neonatal Screen. 2024. PMID: 38920848 Free PMC article.
-
Validity of remote live stream video evaluation of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.PLoS One. 2024 May 16;19(5):e0300700. doi: 10.1371/journal.pone.0300700. eCollection 2024. PLoS One. 2024. PMID: 38753764 Free PMC article. Clinical Trial.
-
Short developmental milestone risk assessment tool to identify Duchenne muscular dystrophy in primary care.Orphanet J Rare Dis. 2024 May 10;19(1):192. doi: 10.1186/s13023-024-03208-8. Orphanet J Rare Dis. 2024. PMID: 38730494 Free PMC article.
-
The complex landscape of DMD mutations: moving towards personalized medicine.Front Genet. 2024 Mar 26;15:1360224. doi: 10.3389/fgene.2024.1360224. eCollection 2024. Front Genet. 2024. PMID: 38596212 Free PMC article. Review.
-
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.J Neuromuscul Dis. 2024;11(2):499-523. doi: 10.3233/JND-230219. J Neuromuscul Dis. 2024. PMID: 38363616 Free PMC article.
References
-
- Emery AE. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul Disord. 1991;1:19–29. - PubMed
-
- Emery AE. Duchenne Muscular Dystrophy. 2. New York: Oxford University Press; 1987.
-
- Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509–17. - PubMed
-
- Dubowitz V. Muscle Disorders in Childhood. 2. Philadelphia: WB Saunders; 1995. Muscular dystrophies.
-
- Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, 3rd, Miller JP, et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol. 1987;44:812–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources

